Nifty
Sensex
:
:
11095.25
37687.91
203.65 (1.87%)
748.31 (2.03%)

Pharmaceuticals & Drugs - Global

Rating :
64/99  (View)

BSE: 532296 | NSE: GLENMARK

445.40
-4.40 (-0.98%)
04-Aug-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  453.95
  •  456.60
  •  442.55
  •  449.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3813439
  •  16985.06
  •  573.05
  •  161.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 12,701.80
  • 16.37
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,212.70
  • 0.44%
  • 2.09

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.62%
  • 2.02%
  • 16.59%
  • FII
  • DII
  • Others
  • 23.4%
  • 2.36%
  • 9.01%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.80
  • 8.11
  • 2.81

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.85
  • 5.48
  • -4.88

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.04
  • 34.58
  • -5.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.00
  • 19.80
  • 15.55

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.02
  • 4.42
  • 2.64

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.56
  • 13.17
  • 9.96

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
2,767
2,563
8%
2,736
2,555
7%
2,815
2,581
9%
2,323
2,166
7%
Expenses
2,302
2,199
5%
2,295
2,120
8%
2,365
2,141
10%
1,981
1,819
9%
EBITDA
466
364
28%
440
435
1%
450
440
2%
342
347
-1%
EBIDTM
17%
14%
16%
17%
16%
17%
15%
16%
Other Income
44
39
13%
33
-109
-
81
140
-42%
2
138
-99%
Interest
98
82
20%
96
89
9%
90
85
5%
93
79
18%
Depreciation
126
81
56%
106
83
28%
94
82
14%
91
79
14%
PBT
318
240
32%
271
154
76%
347
580
-40%
160
327
-51%
Tax
98
79
24%
80
38
113%
92
166
-45%
51
94
-46%
PAT
220
162
36%
191
116
64%
256
414
-38%
109
233
-53%
PATM
8%
6%
7%
5%
9%
16%
5%
11%
EPS
7.81
5.73
36%
6.76
4.12
64%
9.06
14.67
-38%
3.87
8.26
-53%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
10,641
9,865
9,074
9,079
7,562
6,681
5,945
4,969
4,021
2,949
2,480
Net Sales Growth
8%
9%
0%
20%
13%
12%
20%
24%
36%
19%
 
Cost Of Goods Sold
3,699
3,284
2,963
2,552
2,247
1,538
1,786
1,585
1,291
951
784
Gross Profit
6,942
6,582
6,111
6,527
5,315
5,143
4,159
3,384
2,730
1,998
1,696
GP Margin
65%
67%
67%
72%
70%
77%
70%
68%
68%
68%
68%
Total Expenditure
8,943
8,280
7,459
7,043
6,125
5,467
4,854
3,954
3,306
2,357
1,861
Power & Fuel Cost
-
165
137
127
120
109
94
80
0
0
32
% Of Sales
-
2%
2%
1%
2%
2%
2%
2%
0%
0%
1%
Employee Cost
-
2,056
1,872
1,641
1,378
1,213
1,026
783
629
510
290
% Of Sales
-
21%
21%
18%
18%
18%
17%
16%
16%
17%
12%
Manufacturing Exp.
-
725
649
547
957
1,324
337
273
54
41
143
% Of Sales
-
7%
7%
6%
13%
20%
6%
5%
1%
1%
6%
General & Admin Exp.
-
625
526
1,023
491
253
860
679
1,332
855
269
% Of Sales
-
6%
6%
11%
6%
4%
14%
14%
33%
29%
11%
Selling & Distn. Exp.
-
1,125
997
1,065
893
991
524
521
0
0
310
% Of Sales
-
11%
11%
12%
12%
15%
9%
10%
0%
0%
13%
Miscellaneous Exp.
-
299
315
89
39
38
228
34
0
0
310
% Of Sales
-
3%
3%
1%
1%
1%
4%
1%
0%
0%
1%
EBITDA
1,698
1,586
1,615
2,037
1,437
1,214
1,091
1,015
714
592
620
EBITDA Margin
16%
16%
18%
22%
19%
18%
18%
20%
18%
20%
25%
Other Income
160
208
91
37
20
7
11
11
18
144
50
Interest
377
335
286
237
179
190
189
160
147
160
166
Depreciation
417
326
302
264
234
300
217
127
98
95
121
PBT
1,096
1,133
1,119
1,572
1,044
731
697
739
488
482
384
Tax
320
376
315
383
301
334
151
111
24
24
53
Tax Rate
29%
29%
28%
26%
29%
61%
22%
15%
5%
5%
14%
PAT
776
925
804
1,109
743
210
542
620
460
453
324
PAT before Minority Interest
776
925
804
1,109
743
209
546
628
464
458
331
Minority Interest
0
0
0
0
0
0
-3
-8
-4
-5
-7
PAT Margin
7%
9%
9%
12%
10%
3%
9%
12%
11%
15%
13%
PAT Growth
-16%
15%
-28%
49%
255%
-61%
-13%
35%
2%
40%
 
EPS
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31
16.06
11.50

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
5,605
5,163
4,493
3,630
1,783
2,983
2,763
2,402
2,037
2,355
Share Capital
28
28
28
28
27
27
27
27
27
27
Total Reserves
5,566
5,125
4,463
3,600
1,756
2,956
2,736
2,375
2,010
2,328
Non-Current Liabilities
2,280
2,824
3,258
1,499
2,749
1,967
1,625
1,138
519
1,940
Secured Loans
0
0
0
0
0
2,429
1,920
1,312
617
241
Unsecured Loans
3,574
4,142
4,536
2,487
2,574
0
0
0
0
1,628
Long Term Provisions
0
0
0
0
0
0
0
15
7
0
Current Liabilities
4,021
3,288
2,703
3,999
3,777
2,949
2,201
1,902
2,259
519
Trade Payables
2,221
1,870
1,743
1,941
1,948
1,363
1,037
789
657
379
Other Current Liabilities
1,013
691
509
1,137
1,264
973
763
415
110
119
Short Term Borrowings
303
295
187
787
348
353
368
687
1,480
0
Short Term Provisions
484
432
263
134
217
260
33
11
12
20
Total Liabilities
11,906
11,275
10,453
9,128
8,309
7,912
6,614
5,466
4,842
4,827
Net Block
3,670
3,030
2,755
2,594
2,015
2,890
2,406
2,237
2,067
1,787
Gross Block
6,527
5,368
4,770
4,301
3,495
3,633
2,935
2,651
2,383
2,176
Accumulated Depreciation
2,857
2,338
2,015
1,707
1,480
743
529
414
317
388
Non Current Assets
5,209
4,286
3,578
3,224
2,978
3,150
2,887
2,519
2,243
2,406
Capital Work in Progress
1,399
1,122
708
543
477
206
422
248
146
601
Non Current Investment
30
15
16
17
17
0
0
0
0
18
Long Term Loans & Adv.
110
120
99
70
468
33
37
0
0
0
Other Non Current Assets
1
1
0
0
0
20
22
33
31
0
Current Assets
6,697
6,989
6,875
5,904
5,331
4,763
3,727
2,947
2,599
2,421
Current Investments
0
0
0
0
0
0
0
0
0
0
Inventories
2,252
2,031
2,139
1,568
1,269
933
844
788
807
708
Sundry Debtors
2,195
2,332
2,404
2,493
2,512
2,156
1,640
1,244
1,131
1,078
Cash & Bank
938
1,235
1,058
857
776
801
607
322
196
107
Other Current Assets
1,312
811
683
392
774
873
636
594
465
527
Short Term Loans & Adv.
547
581
590
595
743
768
540
519
322
527
Net Current Assets
2,676
3,701
4,172
1,905
1,554
1,814
1,525
1,045
340
1,902
Total Assets
11,906
11,275
10,453
9,128
8,309
7,912
6,614
5,466
4,842
4,827

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,324
1,648
657
345
482
854
648
804
931
352
PBT
1,301
1,119
1,491
1,044
544
697
739
488
482
384
Adjustment
330
571
727
391
523
710
342
484
190
265
Changes in Working Capital
136
309
-862
-612
-267
-290
-268
-35
353
-209
Cash after chg. in Working capital
1,767
2,000
1,356
823
799
1,117
813
937
1,024
440
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-443
-352
-699
-478
-318
-263
-165
-133
-94
-87
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-699
-1,013
-712
-880
-540
-368
-464
-278
-367
-387
Net Fixed Assets
455
-362
-256
-287
-1,355
-112
-178
-55
-41
-53
Net Investments
-56
-1,346
-8
-199
-250
-115
-211
-42
-48
-755
Others
-1,098
695
-448
-394
1,065
-141
-75
-181
-278
421
Cash from Financing Activity
-739
-468
543
699
199
-98
195
-361
-436
70
Net Cash Inflow / Outflow
-114
166
488
163
141
388
379
165
128
36
Opening Cash & Equivalents
1,233
1,056
857
764
795
605
320
195
104
71
Closing Cash & Equivalent
936
1,233
1,056
857
764
795
605
320
195
107

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
198
183
159
129
66
110
102
89
75
87
ROA
8%
7%
11%
9%
3%
8%
10%
9%
9%
7%
ROE
17%
17%
27%
27%
9%
19%
24%
21%
21%
17%
ROCE
16%
15%
21%
19%
12%
15%
18%
14%
15%
14%
Fixed Asset Turnover
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
Receivable days
84
95
97
119
126
115
105
108
137
148
Inventory Days
79
84
74
68
59
54
59
72
94
98
Payable days
97
96
102
117
95
83
68
108
107
68
Cash Conversion Cycle
66
82
69
70
90
86
96
72
124
178
Total Debt/Equity
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
Interest Cover
5
5
7
7
4
5
6
4
4
3

News Update


  • Glenmark declares top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment
    23rd Jul 2020, 09:28 AM

    Favipiravir is a broad spectrum oral antiviral drug that selectively inhibits RNA-dependent RNA polymerase and the viral replication phase of SARS-CoV-2

    Read More
  • Glenmark Pharmaceuticals launches world’s first hypertension awareness symbol
    18th Jul 2020, 13:57 PM

    The symbol is developed in consultation with 50,000 leading doctors in the country, to raise awareness of the growing burden of hypertension

    Read More
  • Glenmark Pharmaceuticals cuts price of antiviral drug Favipiravir
    14th Jul 2020, 09:01 AM

    The company had launched the drug in June at a price of Rs 103 per tablet

    Read More
  • Glenmark commences post marketing surveillance study on FabiFlu
    13th Jul 2020, 11:35 AM

    Glenmark has announced a price reduction of 27% for FabiFlu

    Read More
  • Fitch affirms Glenmark Pharmaceuticals’ rating at ‘BB’ with stable outlook
    13th Jul 2020, 11:08 AM

    The agency has also affirmed Glenmark's $200 million 4.50% senior unsecured notes due 2021 at 'BB'

    Read More
  • Glenmark Pharma - Quarterly Results
    26th Jun 2020, 21:03 PM

    Read More
  • Glenmark gets nod to launch favipiravir for treatment of COVID-19 patients
    20th Jun 2020, 08:53 AM

    The company has received the manufacturing and marketing approval from India's drug regulator

    Read More
  • Glenmark Pharmaceuticals’ arm receives USFDA’s approval for Fingolimod Capsules
    19th Jun 2020, 09:37 AM

    The Gilenya Capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion

    Read More
  • Glenmark Pharmaceuticals’ arm receives USFDA’s approval for Chlorzoxazone Tablets
    27th May 2020, 10:30 AM

    This marks Glenmark’s first ANDA approval out of their new North American manufacturing facility based in Monroe, North Carolina

    Read More
  • Glenmark Pharmaceuticals to test two antiviral drugs Favipiravir, Umifenovir as potential COVID-19 treatment strategy
    26th May 2020, 11:48 AM

    The two antiviral drugs have different mechanism of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stage of disease

    Read More
  • Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India
    12th May 2020, 10:32 AM

    Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India

    Read More
  • Glenmark Pharmaceuticals launches Single Inhaler Triple Therapy AIRZ-FF for COPD
    11th May 2020, 12:24 PM

    This new triple therapy innovation offers significant bronchodilation, reduces risk of severe attacks, and eliminates dependence on multiple inhalers

    Read More
  • Glenmark gets nod to conduct clinical trials on Favipiravir Antiviral tablets on COVID-19 patients
    30th Apr 2020, 09:06 AM

    The product is a generic version of Avigan of Fujifilm Toyama Chemical Co., Japan, a subsidiary of Fujifilm Corporation

    Read More
  • Glenmark Pharma’s arm gets USFDA’s tentative nod for Dapagliflozin, Saxagliptin Tablets
    29th Apr 2020, 10:20 AM

    The Qtern Tablets, 10 mg/5 mg market achieved annual sales of approximately $10.4 million

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.